175 related articles for article (PubMed ID: 37978342)
21. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
22. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
[TBL] [Abstract][Full Text] [Related]
23. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
24. Impact of skeletal muscle mass in patients with recurrent gastric cancer.
Matsunaga T; Satio H; Miyauchi W; Shishido Y; Miyatani K; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
World J Surg Oncol; 2021 Jun; 19(1):170. PubMed ID: 34116681
[TBL] [Abstract][Full Text] [Related]
25. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
26. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
27. Impact of Low Skeletal Muscle Mass on the Prognosis of Patients with Head and Neck Cancer Treated Nonsurgically.
Iwasa YI; Kitoh R; Hiramatsu K; Sugiyama K; Watanabe K; Yasukawa R; Shinagawa J; Miyajima H; Yokota Y; Kobayashi M; Kitano T; Mori K; Takumi Y
ORL J Otorhinolaryngol Relat Spec; 2023; 85(1):36-43. PubMed ID: 36423591
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of the skeletal muscle index and an inflammation biomarker in patients with breast cancer who underwent postoperative adjuvant radiotherapy.
Hua X; Deng JP; Long ZQ; Zhang WW; Huang X; Wen W; Guo L; He ZY; Lin HX
Curr Probl Cancer; 2020 Apr; 44(2):100513. PubMed ID: 31732239
[TBL] [Abstract][Full Text] [Related]
29. The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer.
Ganju RG; TenNapel M; Spoozak L; Chen AM; Hoover A
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):104-112. PubMed ID: 31397078
[TBL] [Abstract][Full Text] [Related]
30. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria.
Beumer BR; van Vugt JLA; Sapisochin G; Yoon P; Bongini M; Lu D; Xu X; De Simone P; Pintore L; Golse N; Nowosad M; Bennet W; Tsochatzis E; Koutli E; Abbassi F; Claasen MPAW; Merli M; O'Rourke J; Gambato M; Benito A; Majumdar A; Tan EK; Ebadi M; Montano-Loza AJ; Berenguer M; Metselaar HJ; Polak WG; Mazzaferro V; IJzermans JNM;
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2373-2382. PubMed ID: 36622940
[TBL] [Abstract][Full Text] [Related]
31. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
32. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
[TBL] [Abstract][Full Text] [Related]
33. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
34. The low cross-sectional muscle index at the third cervical vertebra is a marker for sarcopenia in patients with laryngopharyngeal cancer.
Gundog M; Kiraz E; Eroglu C
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261441
[TBL] [Abstract][Full Text] [Related]
35. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
Rimar KJ; Glaser AP; Kundu S; Schaeffer EM; Meeks J; Psutka SP
Bladder Cancer; 2018 Oct; 4(4):411-418. PubMed ID: 30417052
[TBL] [Abstract][Full Text] [Related]
36. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.
Jin Y; Ma X; Yang Z; Zhang N
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):697-705. PubMed ID: 36720459
[TBL] [Abstract][Full Text] [Related]
37. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
38. Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
Matsunaga T; Satio H; Sakano YU; Makinoya M; Shimizu S; Shishido Y; Miyatani K; Kono Y; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
Anticancer Res; 2023 Nov; 43(11):5051-5059. PubMed ID: 37909949
[TBL] [Abstract][Full Text] [Related]
39. The validation of low-dose CT scans from the [
Zwart AT; Cavalheiro VJ; Lamers MJ; Dierckx RAJO; de Bock GH; Halmos GB; van der Hoorn A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1735-1742. PubMed ID: 36781423
[TBL] [Abstract][Full Text] [Related]
40. Impact of body fat and muscle quantity on short- and long-term outcome after gastrectomy for cancer.
Uchida T; Sekine R; Matsuo K; Kigawa G; Umemoto T; Tanaka K
Clin Nutr; 2022 Jul; 41(7):1467-1474. PubMed ID: 35662018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
